The acid pocket: a target for treatment in reflux disease?
about
Management of the patient with incomplete response to PPI therapy.Exploring the physiologic role of human gastroesophageal reflux by analyzing time-series data from 24-h gastric and esophageal pH recordings.Symptomatic reflux disease: the present, the past and the future.Republished: symptomatic reflux disease: the present, the past and the future.Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover studyMechanisms of Barrett's oesophagus (clinical): LOS dysfunction, hiatal hernia, peristaltic defects.Volume, distribution and acidity of gastric secretion on and off proton pump inhibitor treatment: a randomized double-blind controlled study in patients with gastro-esophageal reflux disease (GERD) and healthy subjects.Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis.Management of the Acid Pocket.Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in ChinaManagement of paediatric GERD.Disruption of the gastroesophageal junction by central obesity and waist belt: role of raised intra-abdominal pressure.Safety of medication options for treating pediatric esophagitis.Effect of alginate in patients with GERD hiatal hernia matters.The Relationship Between the Acid Pocket and GERD.Adult and paediatric GERD: diagnosis, phenotypes and avoidance of excess treatments.Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis.Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptoms.Commentary: revisiting the past--does it hold the key to the future treatment of refractory GERD? Author's reply.The effects of dose and diet on the pharmacodynamics of omeprazole in the horse.Risk factors for erosive and non-erosive gastroesophageal reflux disease and Barrett's esophagus in Nothern Sardinia.Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppressionExpert consensus document: Advances in the physiological assessment and diagnosis of GERD.The impact of the speed of food intake on gastroesophageal reflux events in obese female patients.Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.Preliminary investigations into a novel, long-acting, injectable, intramuscular formulation of omeprazole in the horse.Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.Endoscopic diagnosis of hiatus hernia under deep inspiration is not consistent with esophageal manometric diagnosis.Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.Hepatocyte Transplantation.Prolonged measurement improves the assessment of the barrier function of the esophago-gastric junction by high-resolution manometry.Editorial: refractory GERD-good drug, wrong patients?
P2860
Q27025882-FC064E94-2E15-4161-AFCB-0A5BBB6BF714Q30864197-0C598F6D-5FBC-456C-AF22-D747D8E51271Q33834731-7AB6BF68-0537-452E-9C72-22D3D31795C6Q35048270-E49C8630-0CB8-442D-B7E1-DAD58ED521BBQ35129666-B12B3745-BBFB-4600-B602-15D53616F093Q35162477-220EC382-B713-4E73-B2D8-D59B4E6AA300Q35761321-B793539E-E622-49CC-AE96-891ED88D947FQ36145570-8306E9FC-3C51-45DD-8D81-D4FAF476C1DAQ37190549-0E8004E4-AFFD-4084-A00C-F85FB0C1B945Q37295956-2E274EB1-5BA7-48FC-81D7-82AA6CE99080Q38152645-8E0FA654-9935-49E5-A280-59C71845BBDDQ38191675-AB653E9E-7444-4F4D-9CD3-DDAA5D4C99F1Q38442609-944CE048-60C7-4A43-AB87-D22860AB56E3Q38599589-668FEC1F-65F7-4275-AD9D-9C75352CBDF7Q38713799-7A8F367B-8280-42FC-95F1-82BABEA4DFD4Q38916823-2A1FD7E3-C0EF-4922-9AE6-652992EAF924Q39212872-67CFA5A4-356C-4CA6-9944-9345190B232CQ39218829-14FFACC4-F563-4124-A7E2-314066BDF7BCQ39396442-FA8B64B0-F29D-4D43-99C9-DB5DA37915C8Q39401435-A59AEE69-4C5A-47A9-B934-D69A4F29090FQ39460047-E884C636-0895-4F7F-B66B-B6A7FA2C2865Q40624545-C5AF025B-CB69-4A00-82BB-26182A9C0793Q42371575-9431ED4B-EAB6-47A5-AD77-AFC3378D7FC0Q47915951-D98951A7-FB47-40CB-B33A-1A946725FE32Q48002178-21943091-DDCF-4472-97A1-F450035CA184Q48206271-FDD9C9E2-1CB2-4778-9A41-156C77EE674BQ48291486-C89C4066-BC00-4C26-881B-63E867979513Q49447901-F95F0BFF-B878-4B4B-B456-2398F3ADECBBQ50093750-691C988D-9363-458F-A875-2492447BE85CQ50129556-B1EAD988-14B3-4142-962C-C813FFD46688Q52614686-343D9B25-A93D-4970-8869-5AF0FC2B368CQ53810145-AB670488-20EB-413B-822A-F8CA0B91E1F0Q53945864-AF75C525-5623-4933-865A-F91F1D00799AQ54343643-D7542A9B-AFB5-4C25-B16C-9496D1CFFA55
P2860
The acid pocket: a target for treatment in reflux disease?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The acid pocket: a target for treatment in reflux disease?
@en
type
label
The acid pocket: a target for treatment in reflux disease?
@en
prefLabel
The acid pocket: a target for treatment in reflux disease?
@en
P2093
P356
P1476
The acid pocket: a target for treatment in reflux disease?
@en
P2093
Andre J P M Smout
Daniel Sifrim
Guy Boeckxstaens
Kenneth McColl
Lisa O'Rourke
Peter J Kahrilas
P304
P356
10.1038/AJG.2013.132
P407
P577
2013-04-30T00:00:00Z